Report from IFFGD Research Award Winner

Stress and Irritable Bowel Syndrome: Unraveling the Code

By: Yvette Taché, Ph.D., Director, UCLA CURE Animal Models Laboratory; Associate Director, UCLA CURE Digestive Diseases Research Center; Co-Director, UCLA Oppenheimer Family Center for Neurobiology of Stress; Head, UCLA CURE Brain Gut Research Group; and Professor, Division of Digestive Diseases, University of California – Los Angeles, Los Angeles, CA

Dr. Taché was the recipient of the IFFGD 2005 Research Award to Senior Investigator, Basic Science. Her early publications put the “brain-gut axis” on the map. Since then, she has been one of the pioneers in this field. In many ways, it has been her energy and enthusiasm that has ensured the continued vibrancy of the field. Her identification of the role of corticotrophin-releasing factor (CRF) signaling pathways in stress-related alterations of gut motor function and visceral pain are of major and lasting importance.

At a Glance

“Stress” is a term doctors use to describe normal responses in the body that are needed for health and survival.

Our bodies regularly respond to the constant flow of changes that happen around and within us.

CRF is the brain’s “stress hormone.” When stimulated, it interacts with many systems within the body.

These interactions include those between the brain and the digestive tract. They effect whether or not we feel discomfort or pain, and the way our bowels move.

In some people, the stress response is overactive. When the stress response is out of balance, unwanted symptoms can result.

Understanding how this works will help find new and better ways to treat an illness like IBS.

“No one can live without experiencing some degree of stress all the time. You may think that only serious disease or intensive physical or mental injury can cause stress. This is false. Crossing a busy intersection, exposure to a draft, or even sheer joy are enough to activate the body’s stress mechanisms to some extent.”


Hans Selye, M.D. (1907–1983) is credited to have introduced the term “stress” in the medical field. He defined it as the “stereotyped body response to any demand.” In his pioneer studies reported 70 years ago, he identified key targets altered by a variety of physical and chemical stressors. These included the gut (intestines or bowel), endocrine (glands that control metabolism), and immune (protects the body against foreign substances) systems. His studies are important because some common medical conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), fibromyalgia, and migraine headaches may be stress-related.

IBS can affect 1 in 10 or more people in North America and has a significant worldwide prevalence. It is characterized by chronic or recurrent abdominal pain and/or discomfort associated with changes in bowel habits. These are the key symptoms in the absence of traditionally identifiable structural diseases (e.g., colon cancer, inflammatory bowel disease, etc). The expression of symptoms in IBS reflects a disorder where various factors interact. Among them, psychosocial trauma and high rate of stressful life events (alone or combined with previous episodes of bowel infection/inflammation) have been identified as important risk factors in the onset, severity, and/or persistence of IBS symptoms.

The question is often asked, are psychological conditions a cause or effect of IBS? While not all persons with IBS exhibit psychological distress, it may be present in some patients with IBS, particularly in those with more severe symptoms and who seek health care in highly specialized (tertiary) referral centers. On the other hand, the symptoms of IBS can sometimes be so bothersome and affect daily activities so much that the patient understandably develops emotional distress. Because various forms of emotional stress are important in the development and management of IBS, the understanding of the mind and body’s responses called upon during stress may provide insight on the underlying cause of IBS and open the door to new and more effective treatment.

The Stress Response

A person’s stress response involves a network of brain regions that interact as they receive information from inside or outside the body. When stress activates this network, it triggers two main pathways. One is called the pituitary-adrenal axis, which acts to increase circulating hormones (glucocorticoids – particularly cortisol) involved with regulating the body’s response to stress. The other is the autonomic nervous system, which regulates involuntary bodily functions such as our blood pressure, heart rate, and bowel function. Both of these pathways directly or indirectly
affect gut function through the unique system of nerves within the bowel wall (enteric nervous system). These pathways, along with the brain and enteric nervous system, are collectively referred to as the “brain-gut axis.”

Within the last decade, milestone progress has been achieved in identifying the substances that drive the stress response. One of the most important discoveries is a family of peptides (small proteins made of amino acids) named corticotropin-releasing factor (CRF), urocortin 1, urocortin 2, and urocortin 3. These peptides act as messengers and interact with CRF receptors named CRF1 and CRF2. The receptors are structures on cells that receive a stimulus or message. In turn, they induce a physiological response in the body. These CRF peptides and receptors are located, among other sites, both in the brain and the gut. In the brain, they are located in regions linked with digestive function, emotional behavior, and autonomic nervous system activity. It is increasingly recognized that CRF1 receptors are activated during stress by CRF and urocortin 1. They play a key role in the endocrine, behavioral (mood), and gut responses to stress.

The Role of CRF1 Receptors in IBS Symptoms
Recently, growing evidence indicates that the activation of CRF1 receptors also plays a key role in mediating stress-related changes in colon function, such as muscle contractions or motility, and pain sensitivity. For instance, studies showed that CRF or urocortin 1 acts in the brain stress network to increase anxiety-like behavior, abdominal pain, colon secretions, and muscle contractions (motility). These lead to the development of watery stool/diarrhea, and increased permeability within the lining of the bowel. (The more permeable the bowel lining, the easier it is for substances to pass through, which could allow the passage of bacteria within the intestine into the bowel wall.) The action of CRF in the brain-gut axis brings about changes that occur through the spinal cord and enteric nerve activity.

In addition, studies showed that CRF and urocortin 1 can act directly within the colon where they stimulate secretion and motor activity. In particular, CRF increases mucus and water secretion into the colon from cells lining the colon wall, and activates the enteric nervous system. These responses promote colonic motility, bowel movements, and diarrhea. CRF also stimulates a type of immune cell, called mast cells, to release substances that play a role in increasing permeability, bacterial uptake from inside the colon to the colonic tissue, and pain response. Similarly, when given CRF, muscle contractions in the colon and pain reports increase in IBS patients compared to healthy individuals. When examined under a microscope tissue specimens of the colon from patients with IBS support a possible role of mast cells in affecting abdominal pain. Administration of CRF or urocortin 1 results in many of the features already observed in the symptoms experienced by IBS patients.

Another aspect consistent with a role of CRF pathways in IBS symptoms is findings related to an amplification of information—like turning up the volume of signals—from the gut to the brain. They are increasingly perceived as bothersome gut sensations. Animal studies have shown that painful stimulation of the colon activates brain nerve cells through CRF/CRF1 mechanisms associated with the development of increased vigilance and anxiousness. Therefore, it is conceivable that the increased sensitivity to abdominal pain in IBS patients may cause, in turn, a more pronounced, sustained, and/or frequent activation of CRF/CRF1 pathways. This may lead to increased vigilance, tension, and gut reactivity, which is then, associated with increased IBS symptoms.

Another key piece of evidence supporting the role of CRF pathways in the gut response to stress arises from medication interventions. Here blockade of CRF1 receptors prevented the development of the CRF or stress-related effects described above. For instance, a drug that selectively blocked the CRF1 receptors (CRF1 antagonist) abolished or reduced emotional distress, colonic motility, mucus secretion, mast cell activation, diarrhea, and pain brought on by CRF administration or stress. Blocking CRF receptors in IBS patients has reportedly reduced the increased abdominal discomfort induced by rectal stimulation compared with healthy individuals. In addition, a clinical trial of CRF1 antagonists in people already supports the improvement of mood without side effects. Tricyclic antidepressants (e.g., amitriptyline, desipramine) used in the treatment of IBS may alleviate abdominal pain and bowel symptoms. Interestingly, they also reduce CRF effects in brain regions involved in stimulating anxiety and colon function in animals.

Summary
In summary, these investigational studies reported to date indicate that the activation of CRF1 pathways may result in a combination of effects that are key features of symptoms in some IBS patients. These include stimulation of colonic motility, defecation/watery diarrhea, gut hypersensitivity that increases the perception of stimuli within the bowel (e.g., food, gas, motor contractions), focused attention (hypervigilance) toward gut sensations, and mast cell activation. Blocking the CRF1 receptors may alleviate all these effects. Thus, the conceptual framework emerging supports that sustained activation of the CRF1 system at sites in the brain and/or in the gut may be one component underlying IBS symptoms. Targeting these mechanisms by drugs that block the action of CRF on selected CRF1 receptor sites may lead to treatment that is more effective to reduce IBS symptoms.

Further Reading

About IFFGD
The International Foundation for Functional Gastrointestinal Disorders (IFFGD) is a 501(c)(3) nonprofit education and research organization. We work to promote awareness, scientific advancement, and improved care for people affected by chronic digestive conditions. Our mission is to inform, assist, and support people affected by gastrointestinal disorders. Founded in 1991, we rely on donors to carry out our mission. Visit our websites at: www.iffgd.org or www.aboutIBS.org.

About the Publication
Opinions expressed are an author’s own and not necessarily those of the International Foundation for Functional Gastrointestinal Disorders (IFFGD). IFFGD does not guarantee or endorse any product in this publication or any claim made by an author and disclaims all liability relating thereto. This article is in no way intended to replace the knowledge or diagnosis of your doctor. We advise seeing a physician whenever a health problem arises requiring an expert’s care.

For more information, or permission to reprint this article, contact IFFGD by phone at 414-964-1799 or by email at iffgd@iffgd.org.